Normothermic Machine Perfusion for Liver Transplants
This study is looking at a new way to use donor livers that have some fat (steatotic livers). It uses a device called Normothermic Machine Perfusion (NMP) to improve the quality of these livers before transplant. The goal is to see if NMP can make more livers suitable for transplant, which would help more people needing a liver. You might be able to join if you are between 18 and 80 years old, are waiting for a liver transplant at MGH, and have a MELD-Na score of 25 or less. The study will consider NMP successful if the transplanted livers work well in the first week after surgery. The current status of this study is unclear.
- Study design
- This is an interventional study that plans to enroll 200 participants. It is a single-site study, meaning it will take place at one location.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, early allograft dysfunction, is measured at the first week after transplant.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Early allograft dysfunctionFirst week after transplant
Number of participants with initial poor function of liver allograft: measured by presence of 1 or more of the following: aspartate aminotransferase (AST) level higher than 2000 IU/L (to convert to microkatals per liter, multiply by 0.0167) within the first 7 postoperative days; bilirubin 10 mg/dL or higher (to convert to micromoles per liter, multiply by 17.104) on postoperative day 7; international normalized ratio (INR) of 1.6 or higher on postoperative day 7; or graft primary nonfunction within the first 7 days, defined as irreversible graft dysfunction leading to recipient death or emergency retransplant, in the absence of immunologic or surgical causes